Target Name: USP31
NCBI ID: G57478
Review Report on USP31 Target / Biomarker Content of Review Report on USP31 Target / Biomarker
USP31
Other Name(s): Deubiquitinating enzyme 31 | ubiquitin-specific-processing protease 31 | Ubiquitin specific peptidase 31, transcript variant 1 | ubiquitin specific peptidase 31 | ubiquitin thiolesterase 31 | Ubiquitin specific proteinase 31 | ubiquitin thioesterase 31 | USP31 variant 1 | ubiquitin specific proteinase 31 | Ubiquitin-specific-processing protease 31 | Ubiquitin carboxyl-terminal hydrolase 31 (isoform 1) | Ubiquitin thiolesterase 31 | UBP31_HUMAN | KIAA1203 | Ubiquitin specific protease 31 | Ubiquitin carboxyl-terminal hydrolase 31 | deubiquitinating enzyme 31 | Ubiquitin thioesterase 31

USP31: A Potential Drug Target and Biomarker

Unlike most proteins, USP31 is not a naturally occurring enzyme in the human body. It is an enzyme that has been synthesized in the lab and is currently being studied as a potential drug target and biomarker. USP31 is a 26 kDa protein that is found in various cell types, including muscle, nerve, and heart cells. Its function is to remove a type of protein called colchicine (busulfone) from the cell surface, which can contribute to the development of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The discovery and characterization of USP31 came about through a combination of biochemical, cellular, and structural studies. Researchers identified USP31 as a unique protein that was expressed in high levels in various tissues and cells, including cancer cells, neurodegenerative disease cells, and immune cells . They also found that USP31 was involved in the detoxification of busulfone, which is a toxic compound that can cause damage to cells and contribute to the development of various diseases.

One of the key features of USP31 is its catalytic activity. USP31 is a fast and efficient enzyme that can catalyze the detoxification of busulfone from the cell surface. Studies have shown that USP31 has a high catalytic rate constant (kcat) and a short substrate binding loop, which allows it to efficiently convert busulfone into a less toxic form. This catalytic activity makes USP31 an attractive drug target, as it can be used to treat various diseases that are caused by the overproduction or dysfunction of other enzymes.

Another feature of USP31 is its ability to interact with various molecules, including small molecules, peptides, and proteins. This interactivity makes USP31 a potential biomarker, as it can be used to monitor the effectiveness of different treatments in various diseases. For example, researchers can use USP31 as a marker to assess the effectiveness of anti-cancer drugs by measuring the level of busulfone on the cell surface. They can also use USP31 to monitor the effects of neurodegenerative diseases, such as Alzheimer's disease, by measuring the level of busulfone on the brain.

In addition to its potential as a drug target and biomarker, USP31 also has important implications for the study of cellular signaling pathways. The detoxification of busulfone by USP31 is a critical step in the regulation of various cellular processes, including cell signaling pathways, DNA replication , and apoptosis. This regulation is important for the proper functioning of cells and is implicated in the development of various diseases.

Overall, USP31 is a unique and promising protein that has implications for the study of various diseases. Its catalytic activity and ability to interact with different molecules make it an attractive drug target and biomarker. Further research is needed to fully understand the functions of USP31 and its potential as a therapeutic agent.

Protein Name: Ubiquitin Specific Peptidase 31

Functions: May recognize and hydrolyze the peptide bond at the C-terminal Gly of ubiquitin. Involved in the processing of poly-ubiquitin precursors as well as that of ubiquitinated proteins (By similarity)

The "USP31 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about USP31 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

USP32 | USP32P1 | USP32P2 | USP32P3 | USP33 | USP34 | USP35 | USP36 | USP37 | USP38 | USP39 | USP4 | USP40 | USP41 | USP42 | USP43 | USP44 | USP45 | USP46 | USP46-DT | USP47 | USP48 | USP49 | USP5 | USP50 | USP51 | USP53 | USP54 | USP6 | USP6NL | USP6NL intronic transcript 1 (non-protein coding), transcript variant 1 | USP7 | USP8 | USP8P1 | USP9X | USP9Y | USPL1 | UST | UTF1 | UTP11 | UTP14A | UTP14C | UTP15 | UTP18 | UTP20 | UTP23 | UTP25 | UTP3 | UTP4 | UTP6 | UTRN | UTS2 | UTS2B | UTS2R | UTY | UVRAG | UVSSA | UXS1 | UXT | UXT-AS1 | VAC14 | Vacuolar H+ ATPase | VAMP1 | VAMP2 | VAMP3 | VAMP4 | VAMP5 | VAMP7 | VAMP8 | VANGL1 | VANGL2 | VAPA | VAPB | VARS1 | VARS2 | Vascular endothelial growth factor receptor (VEGFR) | Vascular endothelial growth factors (VEGF) | VASH1 | VASH1-AS1 | VASH2 | VASN | Vasoactive intestinal polypeptide receptor (VIP-R) | Vasohibin | Vasopressin Receptor | Vasopressin V1 Receptor | VASP | VAT1 | VAT1L | VAV1 | VAV2 | VAV3 | VAV3-AS1 | VAX1 | VAX2 | VBP1 | VCAM1 | VCAN | VCL | VCP | VCPIP1